Jump to content

Biomira Says Data Reveals Longer Survival Period For Lung

Recommended Posts

Cancer Patients Taking Stimuvax - Update

http://www.tradingmarkets.com/tm.site/n ... WS/239314/

Friday, April 28, 2006; Posted: 04:50 PM

(RTTNews) - Biomira Inc. (BIOM | charts | news | PowerRating), a biotechnology company, on Friday revealed results from its Phase 2b clinical trial data that tested the clinical potential of Stimuvax in patients with Stage IIIB and IV non-small cell lung cancer. Stimuvax is a synthetic MUC1 peptide vaccine. Revelation of data sent the company's stock up 12.91%.

The Edmonton, Canada-based Biomira said the analysis confirmed that a median survival of 30.6 months was observed in Stage IIIB patients on vaccine, while those people on the control had a median survival of 13.3 months.

The trial enrolled 171 men and women with the disease in a stable stage or who had responded to treatment following completion of their first-line standard chemotherapy with or without radiation therapy.

Alex McPherson, President and CEO of Biomira, said the data are encouraging and have been reviewed by an independent statistician, who confirmed the findings. "We are in the process of completing the transition of this exciting project to Merck KGaA of Darmstadt, Germany and we have begun manufacturing the vaccine required for the phase 3 study slated to start this summer," he added.

BIOM closed Friday's trading session at $1.4001, up $0.1601 from the previous close, on 4.58 million shares.

Link to comment
Share on other sites

  • 2 weeks later...

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.